Published in

Elsevier, Urologic Oncology: Seminars and Original Investigations, 5(31), p. 549-556

DOI: 10.1016/j.urolonc.2011.03.008

Links

Tools

Export citation

Search in Google Scholar

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer

Journal article published in 2013 by Johan F. Langenhuijsen, Dirk Badhauser, Berthold Schaaf, Lambertus A. L. M. Kiemeney, J. Alfred Witjes, Peter F. A. Mulders
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

OBJECTIVES: To analyze the predictive value of PSA for progression and the role of testosterone for quality of life (QOL) in patients with androgen deprivation therapy (ADT) for metastatic prostate cancer. MATERIALS AND METHODS: PSA and testosterone data were used from a phase III trial randomizing patients without progression and PSA /=500 ng/ml was 25%, 55%, and 76% (P = 0.03) in CAD, and 38%, 64%, and 85% (P = 0.006) in IAD, respectively. The 2-year risk of progression for PSA nadir = 0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P